Molecular characterization of the humoral responses to cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization

Journal of Experimental Medicine

Volumn 177, Issue 4, 1993, Pages 1105-1116

  Mukherjee, Jean ^a   Casadevall, Arturo ^a   Scharff, Matthew D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MANNAN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; TETANUS TOXOID;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG CONJUGATION; DRUG EFFECT; GENE REARRANGEMENT; HUMORAL IMMUNITY; HYBRIDOMA; IMMUNIZATION; IMMUNOGLOBULIN GENE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; SURVIVAL;

ANIMAL; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BASE SEQUENCE; CLONE CELLS; CRYPTOCOCCOSIS; DNA, FUNGAL; FEMALE; GENES, IMMUNOGLOBULIN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; POLYSACCHARIDES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETANUS TOXOID; VACCINATION;

EID: 0027403745     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.177.4.1105     Document Type: Article

References (84)

1. Diamond, R.D. 1985. Cryptococcus neoformans. In Principles and Practice of Infectious Disease. Mandell, G.L., R.G. Gordon, Jr., and J.E. Bennett, editors. John Wiley & Sons, Inc., New York. 1460-1468.
2. Zuger, A., E. Louie, R.S. Holtzman, M.S. Simberkoff, and J.J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Arch. Intern. Med. 104:240.
3. Kozel, T.R., and J.R. Cazin, Jr. 1971. Nonencapsulated variant of Cryptococcus neoformans. I. Virulence studies and characterization of soluble polysaccharide. Infect. Immun. 3:287.
4. Bennett, J.E., H.F. Hasenclever, and B.S. Tynes. 1964. Detection of cryptococcal polysaccharide in serum and spinal fluid. Value in diagnosis and prognosis. Trans. Ass. Am. Physician. 77:14.
5. Bloomfield, W., M.A. Gordon, and D.F. Elmendorff, Jr. 1963. Detection of Cryptococcus neoformans antigen in body fluids by latex agglutination. Proc. Soc. Exp. Biol. Med. 114:64.
6. Wilson, D.E., J.E. Bennett, and J.W. Bailey. 1968. Serologic grouping of Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA. 127:820.
7. Ikeda, R., T. Shinoda, T. Fukazawa, and L. Kaufman. 1982. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J. Clin. Microbiol 16:22.
8. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaude-mans. 1978. On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C. Immunochemistry. 15:673.
9. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaude-mans. 1979. On thee structure of the capsular polysaccharide form Cryptococcus neoformans serotype C-II. Mol. Immunol. 16:531.
10. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaude-mans. 1980. Structural studies on the major, capsular polysaccharide from Cryptococcus neoformans serotype B. Carbohydr. Res. 82:103.
11. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaude-mans. 1981. Capsular polysaccharides from a parent strain and from a possible mutant strain of Cryptococcus neoformans serotype ARes. 95:237.
12. Todaro-Luck, F., E. Reiss, R. Cherniak, and L. Kaufman. 1989. Characterization of Cryptococcus neoformans capsular glucuronox-ylomannan polysaccharide with monoclonal antibodies. Infect. Immun. 57:3882.
13. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol. Immunol. 17:1025.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investigations of two capsular polysaccharides from Cryptococcus neoformans. Carbohydr. Res. 86:69.
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B. Prescott. 1982. Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide, f. Immunol. 128:1059.
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect. Immun. 23:644.
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics. 28:417.
18. L usage in polysaccharide binding antibodies. J. Exp. Med. 174:151.
19. Miller, M.F., T.G. Mitchell, W.J. Storkus, and J.R. Dawson. 1990. Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect. Immun. 58:639.
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun. 51:556.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect. Immun. 56:2544.
22. Kozel, T.R., and J.L. Follette. 1981. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect. Immun. 31:978.
23. Levitz, S.M., T.P. Farrell, and R.T. Maziarz. 1991. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J. Infect. Dis. 163:1108.
24. Diamond, R.D. 1974. Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature (Lond.). 247:148.
25. Diamond, R.D., and J.E. Bennett. 1974. Prognostic factors in cryptococcal meningitis. A study of 11 cases. Ann. Intern. Med. 80:176.
26. Dromer, F., P. Aucuoturier, J.-P. Clauvel, G. Saimot, and P. Yeni. 1988. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 20:283.
27. Devi, S.J.N., R. Schneerson, W. Egan, T.J. Ulrich, D. Bryla, J.B. Robbins, and J.E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700.
28. Eckert, T.F., and T.R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895.
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates of polysaccharide from Cryptococcus neoformans. f. Immunol. 98:901.
30. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immunol 55:749.
31. Mukherjee, J., M.D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534.
32. Gadebusch, H.H. 1958. Passive immunization against Cryptococcus neoformans. Proc Soc. Exp Biol. Med. 98:611.
33. Graybill, J.R., M. Hague, and D.J. Drutz. 1981. Passive immunization in murine cryptococcosis. Sabouraudia. 19:237.
34. Dromer, F., J. Barbet, J. Bolard, J. Charreire, and P. Yeni. 1990. Improvement of Amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes. Antimicrob. Agents Ckemother. 34:2055.
35. Dromer, F., and J. Charreire. 1991. Improved Amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:1114.
36. Sanford, J.E., D.M. Lupan, A.M. Schlageter, and T.R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919.
37. Louria, D.B., and T. Kaminiski. 1965. Passively acquired immunity in experimental cryptococcosis. Sabouraudia. 4:80.
38. Casadevall, A., J. Mukherjee, S. Devi, R. Schneerson, J. Robbins, and M.D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1086.
39. Nieto, A., A. Gaya, M. Jansa, C. Moreno, and J. Vives. 1984. Direct measurement of antibody affinity distribution by hapteninhibition enzyme immunoassay. Mol. Immunol. 21:537.
40. Bhattacharjee, A.K., J.E. Bennett, and C.P.J. Glaudemans. 1984. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 6:619.
41. 2b genes are rearranged via switch sequences in MPC-11 cells but only one is expressed. Nucleic Acids Res. 10:611.
42. Max, E.E., J.V. Maizel, Jr., and P. Leder. 1981. The nucleotide sequence of a 5.5-kilobase DNA segment containing the mouse K immunoglobulin J and C region genes. J. Biol. Chem. 256: 5116.
43. bm6. Proc. Natl. Acad. Sci. USA. 83:3371.
44. Devereux, J., P. Haeberli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12:387.
45. Kabat, E.A., T.T. Wu, H.M. Perry, K.S. Gottesman, and C. Foetter. 1991. Sequences of Proteins of Immunological Interest. 5th Ed. U.S. Department of Health and Human Services. U.S. Public Health Service.
46. H genes in the subgroup III. Nucleic Acids Res. 11:7887.
47. H gene segment in subgroup III: a new member of the 7183 gene family. Mol. Immunol. 29:425.
48. Landau, N.R., D.G. Schatz, M. Rosa, and D. Baltimore. 1987. Increased frequency of N-region insertion in a murine pre-B-cell line infected with a terminal deoxynucleotidyl retroviral expression vector. Mol. Cell. Biol. 7:3237.
49. Desderio, S., G.D. Yancopoulos, M. Paskind, E. Thomas, M.A. Boss, N.R. Landau, F.W. Alt, and D. Baltimore. 1984. Insertion of N-regions into heavy-chain genes is correlated with expression of terminal deoxynucleotidyl transferase in B cells. Nature (Lond.). 311:752.
50. Rudikoff, S., M. Pawlita, J. Pumphrey, and M. Heller. 1984. Somatic diversification of immunoglobulins. Proc. Natl. Acad. Sci. USA. 81:2162.
51. Manser, T. 1990. Regulation, timing, and mechanism of antibody V gene somatic hypermutation: lessons from the arsonate system. In Somatic Hypermutation in V-Regions. Steele, E.J., editor. CRC Press, Inc., Boca Raton. 41-54.
52. Litwin, S., and M. Schlomchik. 1990. A test for clonal relatedness in a set of lymphocytes. J. Exp Med. 171:293.
53. Schlomchik, M., M. Mascelli, H. Shan, M.Z. Radic, D. Pisetsky, A. Marshak-Rothstein, and M. Weigert. 1990. AntiDNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp Med. 171:265.
54. Galfre, G., and C. Milstein. 1981. Preparation of monoclonal antibodies: Strategies and procedures. Methods Enzymol. 73:3.
55. + mutations. J. Immunol. 145:2286.
56. Sablitzky, F., G. Wildner, and R. Rajewsky. 1985. Somatic mutation and clonal expansion of B cells in antigen-driven immune response. EMBO (Eur. Mol. Biol. Organ.) J. 4:345.
57. Boswell, C.M., D.C. Irwin, J. Goodnight, and R.E. Stein. 1992. Strain-dependent restricted V„ and V, usage by antibacterial levan monoclonal antibodies. J. Immunol. 148:3864.
58. Perlmutter, R.M., D. Hansburg, D.E. Briles, R.A. Nicolotti, and J.M. Davie. 1978. Subclass restriction of murine anticarbohydrate antibodies. J. Immunol. 121:566.
59. Nahm, M.H., B.L. Clevinger, and J.M. Davie. 1982. Monoclonal antibodies to streptococcal group A carbohydrate. I. A dominant idiotypic determinant is located on V«l. J. Immunol. 129:1513.
60. Sikder, S.R., P.N. Akolkar, P.M. Raladas, S.L. Morrison, and E.A. Rabat. 1985. Sequences of variable regions of hybridoma antibodies to a(1 → 6)-dextran in BALBJc and C57BLJ6 mice. J. Immunol. 135:4215.
61. L regions of murine monoclonal antibodies against 3-fucosyllac-tosamine. J. Immunol. 140:1212.
62. x genes by murine monoclonal antibodies against 3-fucosyllactosamine. Eur. J. Immunol. 19: 1741.
63. Slack, J., G.P. Der-Balian, M. Nahm, and J.M. Davie. 1980. Subclass restriction of murine antibodies. I. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J. Exp Med. 151:853.
64. Mosier, D.E., and B. Subbarao. 1982. Thymus-independent antigens: Complexity of B-lymphocyte activation revealed. Immunol. Today. 3:217.
65. Borden, P., and E.A. Rabat. 1987. Nucleotide sequence of the cDNAs encoding the variable region heavy and light chains of a myeloma protein specific for the terminal nonreducing end of 0f-(1→ 6)-dextran. Proc. Natl. Acad. Sci. USA. 84:2440.
66. L and V„ germ-line genes are used to produce similar combining sites with specificity for a-(l-*-6)-dextrans. J. Immunol. 138:4472.
67. Maizels, N., and A. Bothwell. 1985. The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. Cell. 43:715.
68. Andria, M.L., S. Levy, and E. Benjamini. 1990. Diverse V„ and V,. genes are used to produce antibodies against a defined protein epitope. J. Immunol. 144:2614.
69. Rabat, E.A. 1968. Antigens. In Structural Concepts in Immunology and Immunochemistry. Rabat, E.A., editor. Holt, Rinehart, & Winston, Orlando, FL. 16-41.
70. Sutherland, I.W. 1977. Immunochemical aspects of polysaccharide antigens. In Immunochemistry: An Advanced Textbook. Steward, G., editor. John Wiley & Sons, Inc., New York. 399-443.
71. Berek, C., and C. Milstein. 1987. Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev. 96:23.
72. French, D.L., R. Laskov, and M.D. Scharff. 1989. The role of somatic hypermutation in the generation of antibody diversity. Science (Wash. DC). 244:1152.
73. Padlan, E.A., D.D. Davies, S. Rudikoff, and M. Potter. 1981. Structural basis for the specificity of phosphocholine-binding immunoglobulins. Immunochemistry. 13:945.
74. Fish, S., M. Fleming, J. Sharon, and T. Manser. 1991. Different epitope structures select distinct mutant forms of an antibody variable region for expression during the immune response. J. Exp. Med. 173:655.
75. Cook, W.D., S. Rudikoff, A.M. Guisti, and M.D. Scharff. 1982. Somatic mutation in a cultured mouse myeloma cell affects antigen binding. Proc. Natl. Acad. Sci. USA. 79:1240.
76. Cumano, A., and R. Rajewsky. 1986. Clonal recruitment and somatic mutation in the generation of immunological memory to the hapten NP. EMBO (Eur. Mol. Biol. Organ.) J. 5:2459.
77. Rajewsky, R., I. Forster, and A. Cumano. 1987. Evolutionary and somatic selection of the antibody repertoire in the mouse. Science (Wash. DC). 238:1088.
78. Berek, C., and C. Milstein. 1988. The dynamic nature of the antibody repertoire. Immunol. Rev. 105:5.
79. Foote, J., and C. Milstein. 1991. Rinetic maturation of an immune response. Nature (Lond.). 352:530.
80. Clarke, S.H., R. Huppi, D. Ruezinsky, L. Staudt, W. Gerhard, and M. Weigert. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687.
81. Abrahams, I., and T.G. Gilleran. 1960. Studies on actively acquired resistance to experimental cryptococcosis in mice.J. Immunol. 85:629.
82. Casadevall, A., J. Mukherjee, and M.D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immun. Methods. 154:27.
83. Spiropulu, C., R.A. Eppard, E. Otteson, and T.R. Rozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific to the capsular polysaccharide. Infect. Immun. 57:3240.
84. Sollazzo, M., C.A. Hasemann, R.D. Meek, D. Glotz, J.D. Capra, and M. Zanetti. 1989. Molecular characterization of the V„ region of murine autoantibodies from neonatal and adult BALBJc mice. Eur. J. Immunol. 19:453.